The biologics safety testing market was USD 3,589.5 million in 2022, and it will touch USD 9,370.3 million, with a 12.7% CAGR, by 2030.
The growth is because of the surging incidences of illnesses, growing requirements for biosimilar & biologic drugs, rising funding in research & development, and increasing outsourcing activities.
The vaccines category, based on application, led the industry in 2022, with approximately 30% share. This can be mainly because of the surging occurrence of different ailments over the years.
Moreover, various chronic diseases like cancer and diabetes; as well as infectious illnesses such as measles and influenza; need the administration of vaccines for their management, prevention, or treatment.
The cellular & gene therapy category, on the other hand, will propel at approximately 12% compound annual growth rate, in the coming years. This will be primarily because of the increasing research, along with the improvements in cellular & gene therapies.
North America is the largest contributor to the industry. This will be because of the substantial existence of major companies, the high incidence of serious non-contagious and infectious illnesses like diabetes and coronavirus, respectively; and the developed healthcare infrastructure.
APAC is likely to advance at the fastest compound annual growth rate, of 15%, in the years to come. This is because of the rising incidence of serious illnesses, the large patient pools, and strong government policies backing R&D initiatives in this region.
With the surge in the need for biosimilar as well as biologic medications, the biologics safety testing industry will continue to progress in the coming years.
No comments:
Post a Comment